Clinical trial
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00354250 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00354250 |
|---|---|
| Title | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Advanced Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | ispinesib |
| Enrollment | 60 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2007 |
| First posted | Jul 20, 2006 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: